CanWell Pharma will present latest updates on company clinical development of CAN1012 at ESMO 2025 – Annual Meeting held on October 17-21, 2025 in Berlin. The presentation will be in a poster format during a poster session at the conference. The poster covers newest clinical study updates on the safety and efficacy of our IFN-α biased TLR7 agonist CAN1012 alone or combined with an anti-PD-1 antibody toripalimab from Phase 1 and IIa.
Poster Title (5550): Efficacy of an IFN-α Biased TLR7 Agonist CAN1012 Alone or Combined With the Anti-PD-1 Antibody Toripalimab
Date: October 17-21, 2025
Location: Messe Berlin, Berlin, Germany